default author photo

Rama Raghunandan

PATH

2201 Westlake Avenue, Suite 200

Seattle, WA 98121

United States

SCHOLARLY PAPERS

4

DOWNLOADS

186

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Safety and Immunogenicity of an Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam

Number of pages: 28 Posted: 10 Feb 2022
National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, affiliation not provided to SSRN, Hanoi Medical University, Hanoi Medical University, Hanoi Medical University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Mahidol University, Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), University of Texas at Austin - Department of Molecular Biosciences, affiliation not provided to SSRN, QBI Coronavirus Research Group (QCRG), Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, affiliation not provided to SSRN, affiliation not provided to SSRN, Icahn School of Medicine at Mount Sinai - Department of Microbiology, affiliation not provided to SSRN, affiliation not provided to SSRN, PATH, PATH, PATH, PATH, PATH, PATH, PATH, PATH and PATH
Downloads 63 (933,592)

Abstract:

Loading...

SARS-CoV-2, COVID-19, Newcastle disease virus, Egg-based vaccine

2.

Immune Responses to a Heterologous Booster with Mrna Based Covid-19 Vaccine after Priming with an Inactivated Newcastle Disease Virus Recombinant Vaccine Expressing the Sars-Cov-2 Spike Protein (Ndv-Hxp-S)

Number of pages: 30 Posted: 21 Jan 2025
Mahidol University - Institute of Human Righs and Peace Studies, Mahidol University, Mahidol University, National Center for Genetic Engineering and Biotechnology, Thammasat University, Mahidol University - Vaccine Trial Centre, Mahidol University, affiliation not provided to SSRN, Mahidol University, affiliation not provided to SSRN, affiliation not provided to SSRN, Institute for Disease Modeling, PATH, PATH, affiliation not provided to SSRN, PATH and Mahidol University - Vaccine Trial Centre
Downloads 45 (1,121,190)

Abstract:

Loading...

NDV-HXP-S COVID-19 vaccine, bivalent mRNA booster, immune response

3.

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing Sars-Cov-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial

Number of pages: 26 Posted: 30 May 2024
National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, affiliation not provided to SSRN, PATH, La Jolla Institute for Allergy and Immunology (LIAI), affiliation not provided to SSRN, PATH, PATH, PATH, PATH, La Jolla Institute for Allergy and Immunology (LIAI), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, La Jolla Institute for Allergy and Immunology (LIAI) - Division of Vaccine Discovery, PATH, Icahn School of Medicine at Mount Sinai - Department of Microbiology and La Jolla Institute for Allergy and Immunology (LIAI)
Downloads 41 (1,170,409)

Abstract:

Loading...

SARS-CoV-2, COVID-19, Newcastle disease virus, Egg-based vaccine, Phase II clinical trial

4.

Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 µg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA

Number of pages: 22 Posted: 26 Feb 2026
Ministry of Public Health, Thailand, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, PATH, Institute for Disease Modeling, PATH, PATH, PATH, Ministry of Public Health, Thailand, affiliation not provided to SSRN, Bureau of Policy and Strategy, Nonthaburi, Thailand, affiliation not provided to SSRN, affiliation not provided to SSRN, Government of the United States of America - Influenza Division and affiliation not provided to SSRN
Downloads 37 (1,222,651)

Abstract:

Loading...

COVID-19 vaccine, Phase III clinical trial, inactivated recombinant NDV-HXP-S vaccine, secondary immunization, Thailand.